Sanofi launches Awareness Campaign for Air France passengers on the Risks of Counterfeit Medicines

PR Newswire/Les Echos/ 
Sanofi launches Awareness Campaign for Air France passengers on the Risks of  
                         Counterfeit Medicines 
- Counterfeit medicines represent a threat for public health affecting all 
                          therapeutic areas - 
Paris, France - November 30, 2012 - Sanofi (EURONEXT: SAN and NYSE: SNY)
announced today the launch of an awareness campaign for passengers on Air France
on the risks of counterfeit medicines. As part of the campaign, an educational
film will be shown throughout the month of December 2012 on board long-haul Air
France flights to and from North America, Latin America, Africa, the Middle
East, Asia and the Pacific. The objective is to reach more than 4 million
passengers. These awareness messages will also appear in Air France Magazine and
the Air France airport lounges. 
"We are pleased to launch this campaign to raise awareness on the risks of
counterfeit medicines by reaching out to passengers on Air France, as one of
Sanofi's absolute priorities is to ensure that patients have access to safe and
quality medicines," said Philippe Peyre, Senior Vice President General
Secretary, Sanofi. "Sanofi is mobilized to fight against counterfeit medicines,
which represent a threat for public health, through active cooperation with
governments and international organizations and contribution to various
information and prevention programs." 
Sanofi and its team of internal experts have been involved in the fight against
counterfeit medicines for several years. The Group is focusing its resources on
technological prevention, using innovative solutions to ensure the protection
and traceability of its products, and monitoring and collecting information on
counterfeit of its products through its Central Anti-Counterfeit Laboratory
located in Tours, France. The laboratory is a tool available for authorities in
the fight against counterfeit medicines, and has analyzed over 20,000 suspicious
products since its opening five years ago. 
Sanofi is also involved in the fight against cybercrime and, within this
framework, cooperates with several partners in many initiatives devoted to
fighting counterfeiting activities. Worldwide, Sanofi experts regularly inform
heads of medical institutions, physicians, pharmacists and students on
counterfeit medicine issues. 
Counterfeit medicines are found everywhere in the world. All therapeutic areas
are affected, including innovative and generic drugs. In over 50% of cases,
medicines purchased over the Internet from illegal sites that conceal their
physical address have been found to be counterfeit (1). 
(1) http://www.who. int/mediacentre/factsheets/fs275/en/ 
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT:
SAN) and in New York (NYSE: SNY). 
Sanofi Media Relations
Frédéric Lemonde-San
Tel: +33 (0) 1 53 77 91 55
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication. 
-0- Nov/30/2012 07:41 GMT
Press spacebar to pause and continue. Press esc to stop.